Sage Journals: Discover world-class research

Abstract

Background:

Previous evidence has demonstrated that serum leptin is correlated with appetite in combination with, but not without, modest exercise.

Aim:

The present experiments investigated the effects of exogenous adrenaline and α/β adrenoceptor blockade in combination with moderate exercise on serum leptin concentrations, appetite/satiety sensations and subsequent food intake in obese women.

Methods:

A total of 10 obese women ((mean ± SEM), age: 50 (1.9) years, body mass index 36 (4.1) kg/m², waist 104.8 (4.1) cm) participated in two separate, double-blind randomised experimental trials. Experiment 1: moderate exercise after α/β adrenergic blocker (labetalol, 100 mg orally) versus moderate exercise plus placebo; experiment 2: adrenaline infusion for 20 minutes versus saline infusion. Appetite/satiety and biochemistry were measured at baseline, pre- and immediately post-intervention, then 1 hour post-intervention (i.e., before dinner). Food intake was assessed via ad libitum buffet-style dinner.

Results:

No differences were found in appetite/satiety, subsequent food intake or serum leptin in any of the studies (experiment 1 or experiment 2). In experiment 1, blood glucose was higher (p < 0.01) and plasma free fatty acids lower (p = 0.04) versus placebo. In experiment 2, plasma free fatty acids (p < 0.05) increased after adrenaline versus saline infusion.

Conclusions:

Neither inhibition of exercise-induced adrenergic activity by combined α/β adrenergic blockade nor moderate increases in adrenergic activity induced by intravenous adrenaline infusion affected acute appetite regulation.

Keywords

Appetite regulation adrenaline infusion adrenergic blockade moderate exercise obesity

Introduction

Obesity is the most prevalent single disease in the world (International Classification of Diseases 10 code E.66), with more than 2.1 billion overweight adults (Ng et al., 2013). Better understanding of the mechanisms that regulate food intake, energy expenditure (EE) and energy balance is critical for the prevention and management of obesity. Physical activity has been implicated in appetite and body mass regulation; appetite also seems to be ‘coupled’ with body weight control in individuals undertaking moderate physical activity (Shook et al., 2015). Although physical activity tends to increase food intake (Westerterp et al. 2015), habitual exercisers are able to closely match food intake to EE (Martins et al., 2008); however, the mechanism underpinning the coupling between physical exercise and food intake regulation has yet to be explained.

In experimental rodent models and in cases of congenital obesity, leptin is a key regulator promoting satiety (Farooqi et al., 2009). In humans, leptin concentration is closely correlated to total fat mass (FM; Considine et al., 1996) and physical activity strongly predicts circulating leptin concentrations independently of body FM, suggesting a plausible role of physical activity in leptin sensitivity (Chu et al., 2001). Raised circulating leptin concentrations do not appear to prevent overeating in obese humans, who are considered ‘leptin resistant’ (Lean and Malkova, 2016). Indeed, most models of diet-induced obesity in rodents have presented evidence that obesity causes central and peripheral leptin resistance whereby anorexigenic/orexigenic neurons fail to signal satiety in response to high circulating leptin (Morris and Rui, 2009). Leptin’s transport across the blood-brain barrier is also reduced concurrently with increasing adiposity (Banks and Farrell, 2003). As human obesity is associated with impaired appetite control, this implies that other factors may influence the anorexic effects of leptin.

Several studies have demonstrated the acute regulation of circulating leptin turnover by adrenergic agents and catecholamine (Keller et al., 2005; Scriba et al., 2000) and the role of endogenous catecholamine in the hypothalamic paraventricular nucleus (PVN) has been related to eating or satiety (Wellman, 2000). For example, activation of α2-adrenoceptors in the PVN enhances eating, whereas activation of α1-adrenoceptors inhibits eating (Wellman et al., 1993). Moreover, an acute effect of elevated adrenaline levels on enhanced leptin transport into the brain through activation of predominantly α1-adrenoceptors was found in rats (Banks, 2001). A link between obesity, inactivity and raised circulating leptin concentrations has been clearly demonstrated (Chu et al., 2001), which suggests that high circulating leptin concentrations are ineffective in regulating appetite and body mass when physically inactive. Studies in lean and obese rats suggested that acute and chronic exercise improved the antiorexigenic action of leptin, as well as hypothalamic leptin signalling (Krawczewski et al., 2011; Ropelle et al., 2010).

We also reported an association between circulating leptin and appetite suppression in obese individuals, but only following an acute bout of moderate-intensity exercise (Tsofliou et al., 2003). These studies support a role of exercise in mediating the action of leptin on appetite regulation in the short term. As even light exercise is known to produce a marked stress response in sedentary individuals (Salvadori et al., 2003), the increase in catecholamines that normally accompanies such a response might be responsible for the coupling of leptin and appetite. Adrenaline may facilitate leptin transport into the brain through stimulation of α-adrenoceptors located at the blood side of the blood-brain barrier (Banks, 2001). The purpose of the current study was to investigate the effects of increased circulating adrenaline concentrations by exogenous intravenous administration and the effects of moderate exercise performed during α/β-adrenoceptor blockade on our primary outcomes, appetite-satiety measures and on subsequent food intake in obese women. We also investigated the impact of these interventions on biological markers such as circulating leptin, glucose and free fatty acid (FFA) concentrations, using the association between serum leptin and appetite/satiety sensations as an indirect index of leptin sensitivity.

Material and methods

This study is reported according to the CONSORT guidelines (Schulz et al., 2010) (Figure S1 and Table S1 in Supplementary Files).

Participants

A total of 10 (n = 10) obese but otherwise healthy, premenopausal women (Table 1) gave written informed consent to participate in the study, which was conducted in accordance with the Declaration of Helsinki. The sample size used in this study was based on the primary outcomes of interest such as appetite ratings and ad libitum intake. Using a paired design and a power of 0.8, a minimum of nine participants would be needed to detect a 10 mm difference in postprandial ratings and to detect a 100 kcal difference in ad libitum energy intake (EI) (Lara et al., 2010; Horner et al., 2014). The protocol was approved by the Glasgow Royal Infirmary Research Ethics Committee (01HU009, 02HU002). All participants were in good physical and mental health with normal blood pressure (≤ 140 / ≤ 90 mmHg), non-smokers, on no medication known to affect appetite, not known to be anaemic or hyperlipidemic and not on a special diet. Following eligibility screening and familiarisation with methodological procedures, using a double-blind, crossover design, participants were randomised to the intervention for each experiment (EXP-1 and EXP-2) using an online random number generator (http://www.randomization.com). The order of the trials for each experiment was randomised separately. There was an interval of at least 7 days between trials. In EXP-1 (exercise with either α/β-adrenoceptor blocker or placebo) all 10 eligible participants took part in the study procedures and data analysis whereas in EXP-2 (adrenaline vs saline infusion) results are presented from nine participants; one participant did not continue after EXP-1.

Table 1.

Subject characteristics, n = 10.

Age (years)	50.3 ± 1.9
Weight (kg)	90.2 ± 5.2
Height (cm)	158.0 ± 0.02
BMI (kg^.m⁻²)	36.0 ± 4.1
Waist circumference (cm)	104.8 ± 4.1
Hip circumference (cm)	115.2 ± 3.1
Fat mass (%) predicted by waist measurement	47.7 ± 1.7
Systolic blood pressure (mmHg)	129.6 ± 2.4
Diastolic blood pressure (mmHg)	89.2 ± 1.4

Values are mean ± SEM.

BMI: body mass index.

Concealed treatment allocation was implemented; a person, unrelated to the trial, prepared the treatment allocation using sealed opaque envelopes. Both participants and researchers evaluating the impact of the experiments were blinded to treatment. Intervention agents were dispensed at each visit by two members of the staff not involved in the study.

Experimental design and procedures

Adrenaline was infused (MacCarthy and Bloomfield, 1983; Centers for Disease Control, 2014), raising circulating adrenaline levels to those typically seen during moderate exercise (Lean et al., 1996). On a separate occasion, labetalol, which blocks α₁-, β₁- and β₂-adrenoceptors (MacCarthy and Bloomfield, 1983; McLoughlin et al., 1992) was administered prior to moderate exercise. Participants visited the laboratory on four occasions to participate in four acute interventions with an interval of at least 7 days between trials (Figure 1); EXP-1 involved moderate-intensity exercise with either α/β-adrenoceptor blocker or placebo and EXP-2 adrenaline infusion versus saline infusion. Participants kept diet and physical activity records for 2 days preceding the first experimental trial. These food and activity patterns were replicated before all subsequent trials. Household measures (e.g., glasses, cupfuls, tablespoons, slices, etc.) were used to quantify food and fluid consumption. For each experiment, participants visited the laboratory approximately 5 hours after a standard lunch and the time duration was standardised within subject. On arrival at the laboratory, weight, waist and hip circumference were measured using calibrated scales and inextensible tapes with bone landmarks for anthropometry (Centers for Disease Control, 2014). The body fat percentage was predicted from waist (Lean et al., 1996). Arterialised-venous blood samples (McLoughlin et al., 1992) were collected from an 18G indwelling catheter placed by percutaneous puncture into a vein on the dorsum of a heated hand and a baseline sample (-60 minutes) was taken. Serial blood samples (10 ml) were then drawn at 0, 20 and 80 minutes. Following each blood sample, participants completed a set of self-rating 100 mm visual analogue scales for hunger, desire to eat, prospective food consumption (PFC), satiety and fullness (Stubbs et al., 2000). Throughout each trial, participants were seated in a comfortable environment watching food-related digital versatile DVDs for 60 minutes. Food-related DVDs were intended to direct participants’ attention towards food and eating, to stimulate a familiar form of home entertainment that might reduce anxiety and eating restraint (Bellisle and Dalix, 2001).

Figure 1.

Schematic representation of the study design, EXP 1: Moderate exercise plus adrenergic blocker vs. placebo for 20 min; EXP 2: Adrenaline vs. Saline infusion for 20 min.

After watching the food-related DVDs, participants took part in one of the following interventions on each of the 4 study days. In EXP-1, 60 minutes prior to each of the two exercise trials, participants were given either 100 mg labetalol (Generics UK) or placebo (calcium carbonate). Then the participants were required to walk at a moderate pace (5 km/h) on a motorised treadmill for 20 minutes. This is in line with a previous study of our group that found acute leptin coupling with appetite/satiety measures after a bout of moderate intensity exercise in obese women (Tsofliou et al., 2003).

In EXP-2, a single dose of either adrenaline hydrochloride (i.e., 1:10,000) diluted in normal saline, or normal saline alone was infused intravenously at a rate of 12.5 ng min/kg ideal body mass, via a pump for 20 minutes (Webber et al., 1994) to yield a plasma level not exceeding 1 nmol/L. This dosage ensures the plasma catecholamine concentration will not exceed the level typically measured following moderate-intensity exercise (Gustafson et al., 1990). This dosage aimed to maintain catecholamine concentrations similar to the levels attained by the 20 minutes of moderate exercise (McLoughlin et al., 1992). The DVD was switched off for 20 minutes during each infusion.

Following each intervention, participants continued watching food-related DVDs for another hour. They were then offered a buffet-type dinner comprising 11 food items: roasted chicken breast (200 g), roasted baby potatoes (160 g), onion stuffing (60 g), boiled peas (126 g), boiled carrots (116 g), boiled corn (118 g), tuna cucumber sandwich (176 g), chicken and salad sandwich (178 g), banana (100 g), two apple pies (120 g), potato crisps (26 g) and orange juice (500 ml) and were told to eat as much as they wanted within 1 hour. Each person’s selection from the buffet dinner was analysed for EI and macronutrient content using a computerised version of McCance and Widdowson’s (revised by Holland et al., 1993) food composition tables and relative EI (REI) was calculated for both exercise trials in EXP-1 as EI minus the energy cost of the exercise (Douglas et al., 2015).

Rating of perceived exertion (breathlessness and leg exertion) (Borg, 1982) and heart rate (HR) (Polar Sport Tester, Polar Electro Oy, Finland) were recorded every 10 minutes during the moderate exercise and the infusion interventions. For EXP-1, expired gas was collected in Douglas bags for 5 minutes at rest, and thereafter 1 minute collections were obtained every 10 minutes during the moderate exercise interventions. Expired gases were analysed within 5 minutes of collection for O₂ (Servomex 570A, East Sussex, UK) and CO₂ (Servomex 1400 B4, East Sussex, UK), volume (dry gas meter, Harvard Apparatus Ltd., Hertfordshire, UK) and temperature (C6600 10-Channel Microprocessor, Comark, Hertfordshire, UK). Barometric pressure was measured using a standard mercury barometer. Oxygen uptake (VO₂), carbon dioxide production (VCO₂) and respiratory exchange ratio (RER, i.e., VO₂/VCO₂) were subsequently evaluated and the percentages of fuel oxidation were determined. EE (kcal·min⁻¹) (Ravussin et al., 1985) and the rates of fat and carbohydrate oxidation (g·min⁻¹) (Alkahtani, 2014) were calculated by standard equations: EE = {4.686 + [(RER − 0.707) / 0.293] x 0.361} x VO₂; fat oxidation = (1.67 x VO₂) − (1.67 x VCO₂); carbohydrate oxidation = (4.55 x VCO₂) − (3.21 x VO₂).

Blood treatment and analyses

Venous blood was collected in K3EDTA vacutainers for the measurement of blood glucose, plasma free fatty acids (FFA) (colorimetric method, Boehringer Mannheim Biochemica, London, UK) and into clot activator vacutainers for serum leptin measurement. Duplicate aliquots (400 µl) of whole blood from the K3EDTA tube were rapidly deproteinised in 800 µl of 0.3 mol^.l⁻¹ perchloric acid; following centrifugation the supernatant was used for the measurement of glucose (Maughan, 1982). Plasma supernatant was separated and plasma (500 μl) was mixed with 50 µl EGTA-glutathione and stored at -70°C for subsequent determination of adrenaline and noradrenaline (NA) (Forster and Macdonald, 1999). The remaining plasma was stored at −20°C and later used for the measurement of FFA (colorimetric method, Boehringer Mannheim Biochemica, London, UK). Blood collected in the clot activator vacutainer was allowed to clot for 10 minutes. Following centrifugation, the serum was stored at -70°C and subsequently analysed for leptin by radioimmunoassay.

Statistical analysis

Statistical analyses were carried out with IBM SPSS v22 for Windows. To assess the impact of interventions, statistical analysis of the data was carried out using General Linear Model with repeated measures followed by pairwise analysis with Bonferroni adjustment. Results are presented as estimated marginal means ± SEM. Correlation analysis was also carried out between the serum leptin concentrations and appetite measures (for each time point separately) and adiposity indices. Statistical significance was taken as p < 0.05.

Results

Effects on self-reported appetite-satiety ratings and subsequent dietary intake

Profiles of hunger, desire to eat, PFC, fullness and satiety throughout each intervention in both experiments are shown in Figures 2(a) and 2(b). In both EXP-1 and EXP-2, a main time effect was observed in all appetite-satiety measures and there were no significant differences on appetite/satiety measures between interventions.

Figure 2.

Mean ± SEM profiles of self-reported appetite-satiety ratings in the Moderate exercise plus a/b blocker (•) and Moderate exercise plus placebo (ˆ) trials (2a, left side), and in the Adrenaline infusion (▪) and Saline infusion (□) trials (2b, right side); ^§||: are significantly different from baseline within the Moderate exercise plus a/b blocker (•^§) or the Moderate exercise plus placebo (ˆ^||) trial and within the Adrenaline infusion (▪^§) or the Saline infusion trials (□^||), p < 0.001.

In EXP-1, the general linear model showed a significant time effect for hunger ratings (p = 0.003), satiety, desire to eat and for PFC ratings (p = 0.002). No differences were found over time in PFC or fullness ratings (Figure 2(a), left side). In EXP-2 there was a significant time effect for hunger, satiety, fullness, PFC and for the desire to eat (p < 0.001) (Figure 2(b), right side).

Self-selected food intake at dinner did not differ significantly between trials in either EXP-1 or EXP-2 (Table 2).

Table 2.

Buffet-style dinner intake subsequent to all interventions.

Dietary intake	Exerciseplus placebo, n = 10	Exerciseplus α/β blocker, n = 10	p value	Adrenaline infusion, n = 9	Salineinfusion, n = 9	p value
Energy intake (kcal)	812.7 ± 75.9	899.9 ± 64.7	0.23	1023.3 ± 81.2	1013.2 ± 79.7	0.85
Protein (g)	57.1 ± 6.6	59.2 ± 5.5	0.48	67.8 ± 7.6	65.2 ± 6.1	0.43
Protein (%)	28 ± 1.6	27 ± 2.3	0.67	26.5 ± 2.2	27 ± 2.1	0.92
Carbohydrate (g)	103.4 ± 8.2	112.8 ± 7.9	0.41	124.9 ± 9.6	120.2 ± 11.5	0.43
Carbohydrate (%)	50 ± 2.7	48 ± 3.1	0.62	47 ± 2.8	45 ± 1.7	0.10
Fat (g)	21.5 ± 2.7	26.1 ± 3.6	0.17	31.3 ± 3.4	33.1 ± 3.4	0.48
Fat (%)	22 ± 1.5	25 ± 6.8	0.30	26± 1.3	28 ± 4.2	0.06

Data are shown as mean ± SEM; no significant differences between interventions in both EXP-1 and EXP-2 (paired t-test).

EXP: experiment.

Effects on biochemical measures in both experiments

In EXP-1 there was no effect of intervention (p = 0.6) and time by intervention interaction (p = 0.4) for serum leptin. Significant differences were found in blood glucose and plasma FFA between the two moderate exercise interventions. Blood glucose concentrations were significantly higher and plasma FFA was significantly lower for 1 hour after the moderate exercise plus α/β blocker intervention compared to exercise plus placebo (Table 3).

Table 3.

Serum leptin, blood glucose, plasma FFA during EXP-1, n = 10.

	Interventions	(-60 min)	(0 min)	(20 min)	(80 min)	Time	Intervention	Intervention x time
Serum leptin (ng^.ml⁻¹)	Exercise plus placebo	62.28± 6.99	65.71 ± 8.39	73.01 ± 8.45	65.65 ± 7.41	p = 0.0004	p = 0.694	p = 0.406
	Exercise plus α/β blocker	62.75± 7.27	63.37 ± 7.33	68.90 ± 7.5	65.24 ± 7.84
Blood glucose (mmol^.l⁻¹)	Exercise plus placebo	4.63 ± 0.16	4.53 ± 0.08	4.55 ± 0.09	4.52 ± 0.06	p = 0.659	p = 0.0004	p = 0.028
	Exercise plus α/β blocker	4.59 ± 0.16	4.83 ± 0.11	4.91 ± 0.07^a	4.89 ± 0.06^a
Plasma FFA (mmol^.l⁻¹)	Exercise plus placebo	0.61 ± 0.13	0.65 ± 0.08	0.74 ± 0.09	0.73 ± 0.07	p = 0.866	p = 0.101	p < 0.001
	Exercise plus α/β blocker	0.67 ± 0.11	0.59 ± 0.07	0.49 ± 0.06^a	0.59 ± 0.06^a

Values are estimated marginal means ± SEM. Analysis was conducted by GLM with repeated measures adjusted for multiple comparisons using Bonferroni corrections.

^a Significant differences between exercise interventions (exercise plus α/β blocker vs exercise plus placebo: glucose 20 minutes, p = 0.001, 80 minutes (after dinner) p < 0.001; FFA 20 minutes, p = 0.02, 80 minutes (after dinner) p = 0.005).

EXP: experiment; FFA: free fatty acids; GLM: General Linear Model.

In EXP-2 there was no significant difference on serum leptin concentrations and blood glucose concentrations between the adrenaline and the saline infusions or over time, throughout the trials (p > 0.05). Plasma concentrations of FFA were significantly higher immediately after the adrenaline infusion compared to saline infusion (FFA, p = 0.032). In addition, plasma NA concentrations showed a borderline significant difference between treatments (Table 4).

Table 4.

Serum leptin, blood glucose, plasma FFA, plasma adrenaline and noradrenaline (NA) concentrations during the EXP-2, n = 9.

						p value
	Interventions	(-60 min)	(0 min)	(20 min)	(80 min)	Time	Intervention	Intervention x Time
Serum leptin (ng^.ml⁻¹)	Adrenaline infusion	63.68 ± 7.77	63.20 ± 8.11	61.98 ± 8.58	67.70 ± 10.49	p = 0.068	p = 0.688	p = 0.961
	Saline infusion	65.80 ± 8.15	65.86 ± 8.07	65.31 ± 9.18	68.90 ± 7.73
Blood glucose (mmol^.l⁻¹)	Adrenaline infusion	4.79 ± 0.34	4.59 ± 0.09	4.76 ± 0.82	4.530 ± 0.07	p = 0.136	p = 0.696	p = 0.532
	Saline infusion	5.03 ± 0.27	4.72 ± 0.06	4.60 ± 0.05	4.575 ± 0.03
Plasma FFA (mmol^.l⁻¹)	Adrenaline infusion	0.75 ± 0.15	0.84 ± 0.13	1.09 ± 0.17^a	0.82 ± 0.11	p = 0.010	p = 0.025	p = 0.083
	Saline infusion	0.56 ± 0.11	0.57 ± 0.13	0.65 ± 0.15	0.70 ± 0.10
Plasma adrenaline (nmol^.l⁻¹)	Adrenaline infusion	–	0.17 ± 0.26	–	–
	Saline infusion	–	0.16 ± 0.20	–	–
Plasma NA (nmol^.l⁻¹)	Adrenaline infusion	–	1.59 ± 0.19	2.32 ± 0.19	–	p = 0.010	p = 0.063	p = 0.060
	Saline infusion	–	1.49 ± 0.26	1.61 ± 0.26	–

Values are estimated marginal means ± SEM. Analysis was conducted by ANOVA with repeated measures adjusted for multiple comparisons using Bonferroni corrections.

^a Significant differences between infusion trials (adrenaline infusion vs saline infusion: at 20 min FFA; p = 0.032) (pairwise comparisons, adjustment for multiple comparisons: Bonferroni). Post-adrenaline infusion values of circulating adrenaline concentrations were not determined due to unresolved co-eluting peaks with adrenaline.

ANOVA: analysis of variance; FFA: free fatty acids.

Baseline serum leptin concentrations correlated significantly with body mass index (BMI, kg^.m⁻²), FM (%) and waist circumference (BMI r = 0.78, p = 0.01, FM r = 0.63, p = 0.04, waist r = 0.71, p = 0.02). No significant associations were found between serum leptin concentrations and appetite-satiety measures at any time point in the two experiments (p > 0.05).

Physiological responses to treadmill walking and adrenaline infusion

HR, perceived breathlessness and leg tiredness during the moderate exercise and the infusion interventions are show in Table 5; there was no significant difference in HR between trials in either EXP-1 or EXP-2 (Table 5). The average EE of participants was 136 kcal (± 30) and 128 (± 40) in exercise plus placebo and exercise plus α/β blocker respectively; the EE was not significantly different between exercise trials. In both EXP-1 and EXP-2, oxygen uptake (VO₂), carbon dioxide production (VCO₂), RER and fuel Fat, Carbohydrate (CHO) oxidation rates were not significantly different between trials (Table 6).

Table 5.

Heart rate, perceived breathlessness and leg-tiredness during the exercise and infusion interventions in both experiments.

			Time (min)				p-value
	Interventions	Rest	5	10	15	20	Time	Intervention	Intervention x time
Heart rate (beats.min⁻¹)	Exercise plus placebo	79.83 ± 7.39	121.33 ± 9.93	132.17 ± 11.13	131.17 ± 8.87	134.33 ± 10.94	<0.001	0.572	0.146
	Exercise plus α/β blocker	86.50 ± 6.24	119.83 ± 18.43	128.17 ± 10.62	125.83 ± 7.56	130.67 ± 11.02
	Adrenaline infusion	76.60 ± 5.28	75.40 ± 4.93	78.00 ± 4.95	81.20 ± 3.63	81.80 ± 3.99	0.016	0.098	0.053
	Saline infusion	76.00 ± 5.21	73.50 ± 4.87	75.00 ± 6.04	74.20 ± 5.61	75.40 ± 4.53
Perceived breathlessness (rating 0–20)	Exercise plus placebo	7.83 ± 0.70	9.83 ± 0.54	11.17 ± 0.65	11.50 ± 0.81	12.33 ± 0.53	<0.001	0.468	0.758
Perceived breathlessness (rating 0–20)	Exercise plus α/β blocker	7.17 ± 0.17	10.00 ± 0.76	11.00 ± 0.67	12.17 ± 0.48	12.33 ± 0.33
	Adrenaline infusion	8.29 ± 0.78	7.71 ± 0.64	8.00 ± 0.66	7.71 ± 0.64	7.71 ± 0.644	0.461	0.458	0.394
	Saline infusion	7.86 ± 0.63	8.00 ± 0.66	8.00 ± 0.66	7.86 ± 0.63	7.857 ± 0.634
Perceived leg-tiredness (rating 0–20)	Exercise plus placebo	7.33 ± 0.42	10.67 ± 0.67	11.50 ± 0.56	12.33 ± 0.72	12.50 ± 0.34	<0.001	0.475	0.490
Perceived leg-tiredness (rating 0–20)	Exercise plus α/β blocker	8.00 ± 0.63	10.33 ± 0.61	11.83 ± 0.83	12.83 ± 0.60	13.33 ± 0.76
	Adrenaline infusion	7.50 ± 0.46	7.50 ± 0.46	7.75 ± 0.62	7.63 ± 0.53	7.63 ± 0.53	0.252	0.039	0.732
	Saline infusion	8.50 ±0.66^a	8.75 ±0.73^a	8.75 ± 0.73	8.75 ± 0.73^a	8.75 ± 0.73^a

Values are estimated marginal means ± SEM. Analysis was conducted by General Linear Model (GLM) with repeated measures adjusted for multiple comparisons using the Bonferroni corrections.

^a Significant differences between infusion interventions (adrenaline infusion versus saline infusion: perceived leg-tiredness (rest p = 0.033, 5 min, 15 min and 20 min, p = 0.038).

Table 6.

Gas exchange, energy expenditure and substrate oxidation in EXP-1 (at rest and during 20 min of exercise) and in EXP-2 (at rest and during 20 min of adrenaline/saline infusion.)

	Trials	Rest	20 min intervention
VO₂ (L.min⁻¹)	Exercise plus placebo	0.3 ± 0.04	1.4 ± 0.3
	Exercise plus α/β blocker	0.3 ± 0.06	1.3 ± 0.4
	Saline infusion	0.2 ± 0.09	0.3 ± 0.05
	Adrenaline infusion	0.3 ± 0.06	0.3 ± 0.05
VCO₂ (L.min⁻¹)	Exercise plus placebo	0.2 ± 0.06	1.1 ± 0.2
	Exercise plus α/β blocker	0.2 ± 0.07	1.1 ± 0.3
	Saline infusion	0.2 ± 0.07	0.2 ± 0.04
	Adrenaline infusion	0.2 ± 0.05	0.2 ± 0.03
Energy expenditure (kcal·min⁻¹)	Exercise plus placebo	1.3 ± 0.1	6.8 ± 1.5
	Exercise plus α/β blocker	1.3 ± 0.3	6.4 ± 2.0
	Saline infusion	1.1 ± 0.4	1.2 ± 0.2
	Adrenaline infusion	1.3 ± 0.3	1.4 ± 0.2
CHO oxidation (g·min⁻¹)	Exercise plus placebo	0.08 ± 0.33	0.58 ± 0.45
	Exercise plus α/β blocker	0.10 ± 0.15	0.55 ± 0.27
	Saline infusion	0.06 ± 0.15	0.07 ± 0.09
	Adrenaline infusion	0.08 ± 0.12	0.03 ± 0.15
Fat oxidation (g·min⁻¹)	Exercise plus placebo	0.10 ± 0.13	0.48 ± 0.21
	Exercise plus α/β blocker	0.09 ± 0.04	0.45 ± 0.15
	Saline infusion	0.10 ± 0.06	0.15 ± 0.07
	Adrenaline infusion	0.10 ± 0.06	0.14 ± 0.07

Values are estimated marginal means ± SEM. No significant differences were found between trials in EXP-1 or EXP-2.

CHO: Carbohydrate; EXP: experiment.

Discussion

In the current study, we examined the effects of exogenous adrenaline and α-/β-adrenoceptor blockade in combination with moderate exercise on serum leptin concentration, appetite/satiety sensations and food intake in obese women. It was envisaged that this approach would allow us to identify whether adrenergic stimulation mediates the central effect of leptin on appetite regulation. The novel result of the current study is that moderate manipulation of adrenergic activity via adrenaline infusion or α/β-adrenoceptor blockade using 100 mg labetalol during moderate-intensity exercise was not found to affect post-exercise appetite/satiety sensations and subsequent EI in obese women.

Previous studies have shown impaired catecholamine responses to physical exercise in obese individuals (Salvadori et al., 2003). In the current study, plasma NA concentration increased to 2.3 nmol·l⁻ ¹ at the end of the adrenaline infusion (only borderline significance was found), typical of the suppressed levels found during exercise in obesity; substantial variation was reported in NA concentration during intense or exhaustive exercise in obese, young individuals (from 4.28 to 5.9 nmol·l⁻¹) (Zouhal et al., 2013). HR tended to increase towards the end of the adrenaline infusion (82 b.min⁻¹) at similar levels with previous adrenaline infusion studies in obese women (Walsh et al., 1998) but we did not observe significant differences; plasma FFA reached concentrations of 1.09 mmol·l⁻¹, which is indicative of adrenaline-stimulated lipolysis (Webber et al., 1994). We were not able to determine post-adrenaline infusion values of circulating adrenaline concentrations due to unresolved peaks co-eluting with adrenaline. However, the plasma FFA profiles would be consistent with responses to plasma adrenaline concentrations above 0.6 nmol·l⁻¹ (∼0.8 nmol·l⁻¹ during 20 minutes of 12.5 ng per kg IBW (Ideal Body Weight) per minute adrenaline infusion), a level that would stimulate lipolysis (Webber et al., 1994).

Catecholamines have long been implicated in appetite regulation as clinical appetite suppressants in obese patients (Lean and Finer, 2006) and it is demonstrated that they exert regulatory effects on the expression of mRNA leptin and circulating leptin concentrations (Ricci and Fried, 1999). The current study is the first to investigate the role of short-term increases in adrenergic activity on the acute appetite response following exercise in humans. It was observed that 20 minutes of adrenaline infusion did not affect acute appetite or serum leptin concentration and leptin concentrations did not change after 20 minutes of moderate-intensity exercise. This is in agreement with others that found decreases in leptin only after prolonged moderate intensity exercise in trained men (Zaccaria et al., 2013) and overweight women (Tiryaki-Sonmez et al., 2013) or a delayed leptin reduction in active individuals within a 24 hour timeframe post-exercise (King et al., 2015). Notably, exercise-induced NA increase but not other biochemical factors (i.e., cortisol or FFA) was suggested to account for the reduction in post-exercise circulating leptin (Zaccaria et al., 2013). However, these studies either did not measure subsequent effects on appetite/satiety feelings post exercise or found no compensatory appetite response (King et al., 2015). As the exercise-induced appetite regulatory response, both hormonal and behavioural, might diverge in the presence of obesity (Heden et al., 2013), whether there is an interplay between adrenergic activity, leptin response and appetite expression after exercise remains to be clarified utilising different modes of exercise in individuals with different body weights.

Furthermore, research in physical exercise and appetite regulation has shown that single bouts of exercise might suppress the orexigenic ghrelin while simultaneously elevating anorexigenic signals peptide YY (PYY), glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK) and pancreatic polypeptide (PP) (Zouhal et al., 2019). These observations have been reported mainly in lean, physically active males whereas evidence in females and particularly in individuals with obesity is sparse and contradictory. It is also suggested that exercise training in women with obesity might influence the regulation of food intake via improved leptin sensitivity (Martins et al., 2013). New evidence from animal studies indicates that leptin might enhance the effects of gut-satiety hormones, highlighting the importance of interactions among the feeding-related hormones that probably lead to an integrated anorectic signal (Akieda-Asai et al., 2014). Future studies need to measure leptin in conjunction with the other appetite-regulating peptides (acylated ghrelin, PYY, GLP-1, CCK and PP) to enable a better understanding of how exercise-induced responses to appetite-regulating hormones might differ in obesity (Dorling et al., 2018).

With regard to the effect of adrenaline infusion on acute appetite control in obese women, previous studies reported reduced circulating leptin concentrations after 60 minutes of adrenaline infusion (0.010 μg/kg fat free mass/min), suggesting that a decrease in obesity-related leptinemia could stimulate a compensatory appetite response but this was not assessed (Couillard et al., 2002). The lack of any significant adrenaline-induced decrease in serum leptin concentrations in the present study may be due to the shorter period of adrenaline infusion compared to previous studies, which found reduced circulating leptin levels after infusions of 60 to 180 minutes (Couillard et al., 2002). Secondly, the large variability in leptin response to adrenaline previously observed in human obesity, namely, low- and high-leptin responders, could account for the present unchanged leptin concentrations during adrenaline infusion and could indicate a potential heterogeneity in leptin sensitivity among obese individuals (Couillard et al., 2002). It is possible that adrenaline-induced changes in leptin could induce changes in appetite/satiety sensations and food intake in the short term, but additional work is necessary to understand the complexity of this physiological mechanism, the timeframe of its action and whether there are differences in the regulation of appetite and food intake between low- and high-leptin responders to adrenaline.

The current study was not able to reproduce the association between leptin and appetite sensations that was found in our earlier study (Tsofliou et al., 2003). There was no evidence for a difference in EI 1 hour after the moderate exercise with placebo (average 813 kcal) compared to α/β-adrenergic blockade (average kcal 900) (p = 0.2). When the REI was additionally calculated for the exercise trials, no difference in REI incurred between exercise with placebo (677 kcal) and exercise with α/β-adrenergic blockade (772 kcal). Previous data from walking studies reported no compensatory response in absolute EI in lean and obese individuals and no changes in relative EI or a significant decrease when the median energy deficit of exercise was around 335 kcal (Schubert et al., 2013). The present findings indicate that α/β-adrenergic blockade was not able to induce a different appetite response to exercise with placebo and did not trigger a compensatory response in EI and appetite sensations after an acute exercise-induced energy deficit. These findings, however, were derived from a small sample and require further verification.

In the present study, labetalol 100 mg resulted in a lower plasma FFA concentration immediately after and 1 hour after moderate exercise (0.49 nmol.l⁻¹, 0.59 nmol.l⁻¹ respectively) compared to placebo (0.74 nmol.l⁻¹, 0.73 nmol.l⁻¹ respectively) possibly by blocking the β-receptor mediated lipolysis (Ladage et al., 2013). The α/β-adrenergic blockade also induced a significant increase in post-exercise blood glucose concentration (4.9 mmol.l⁻¹) compared to placebo (4.5 mmol.l⁻¹). These results are supported by earlier studies (Hartling et al., 1980). However, they are disputed by recent reports suggesting that β blockers differ in terms of their mechanism of action and their effects on glucose and lipid metabolism with respect to their molecular pharmacological mechanisms (Ladage et al., 2013) and particularly, nonvasodilating β blockers are associated with a worsening of glycaemic and lipidic control at rest (Fonseca, 2010). With regard to α blockade, 100 mg labetalol did not produce significant differences in resting and post-exercise HR. This is in line with previous studies showing that labetalol at doses of 100, 200 and 400 mg did not alter resting HR compared to placebo in healthy males (Beachen et al., 2002). However, little evidence has indicated a dose-dependent reduction in post-exercise HR at 1 and 2 hours (Tham et al., 1993).

The present findings suggest that combined α/β-adrenergic blockade during moderate-intensity exercise does not influence appetite/satiety sensations or subsequent food intake following exercise in obese women. The changes in blood glucose and plasma FFA suggest 100 mg of α/β-adrenergic blocker was sufficient to induce β-adrenergic blockade. Labetalol was chosen as a safe and well understood α/β blocker; however, it has greater affinity for β- than α-adrenoceptors (MacCarthy and Bloomfield, 1983). For this reason, any conclusions with respect to α-adrenoceptor blockade should be drawn with caution. Labetalol decreased circulating FFA and increased glucose concentrations, which indicate inhibition of catecholamine-stimulated lipolysis and confirm the primarily β-adrenoceptor blockade. There is no simple way to know if α blockade was adequate. There is evidence that attributes the anorexigenic effect of catecholamines to α-adrenoceptors in the brain (Wellman et al., 1993). It is this effect that a popular class of anti-obesity drugs exploits to reduce eating behaviour (e.g., sibutramine) by blocking NA reuptake through activation of brain α₁-adrenoceptor receptors (Lean, 2001).

Study limitations

The monitoring period of appetite response was relatively brief in our study. According to recent findings, changes in appetite hormones could emerge over the following 24 hours (King et al., 2015). Determining the EI response might also require multiple ad libitum meals, rather than single feeding episodes (Deighton and Stensel, 2014). In our study, all women were premenopausal but menstrual cycle was not controlled for in the study design to account for the perceived confounding effect of the menstrual cycle on appetite sensations, appetite-regulating hormones and EI (Brennan et al., 2009). However, we did not find any differences in appetite responses and EI between the interventions, which could have been confounded by cyclical changes in sex hormones in our women.

Conclusions

In conclusion, inhibition of exercise-induced adrenergic activity by combined α/β-adrenergic blockade and moderate increases in adrenergic activity induced by intravenous adrenaline infusion did not significantly affect acute appetite ratings or ad libitum intake in obese premenopausal women. Testing with a more potent α blockade may be necessary to trigger a detectable effect and elucidate the role of adrenergic activity in exercise-induced anorexia. In this way we could conclude with complete confidence that the observed anorexic effect of exercise on appetite in obese women is not mediated by increased adrenergic activity. Finally, to definitively exclude sympathetic system involvement in exercise-related appetite regulation, the effects of more selective α-adrenergic stimulation on leptin-mediated appetite sensitivity after exercise should be investigated.

Supplemental material

Suppplementary_files - The effects of moderate alterations in adrenergic activity on acute appetite regulation in obese women: A randomised crossover trial

Suppplementary_files for The effects of moderate alterations in adrenergic activity on acute appetite regulation in obese women: A randomised crossover trial by Fotini Tsofliou, Yannis P Pitsiladis, Jose Lara, Marios Hadjicharalambous, Ian A Macdonald, Mike A Wallace and Mike E J Lean in Nutrition and Health

Footnotes

Acknowledgements

We thank the study participants for their dedication and effort.

Author contributions

FT, YPP and MEJL conceived and designed the studies, oversaw its implementation and contributed to the writing of the manuscript. MH supported acquisition of data and contributed to the revision of the manuscript. AMW, JL and IAM contributed in data analysis. FT wrote the first draft of the manuscript. All authors contributed to the interpretation of data and approved the final manuscript.

Ethical statement

The study was conducted in accordance with the declaration of Helsinki and the protocol was approved by the Glasgow Royal Infirmary Research Ethics Committee.

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

ORCID iD

Fotini Tsofliou

Supplemental material

Supplemental material for this article is available online.

References

Akieda-Asai

Poleni

Date

(2014 ) Coinjection of CCK and leptin reduces food intake via increased CART/TRH and reduced AMPK phosphorylation in the hypothalamus. American Journal of Physiology Endocrinology and Metabolism 306(11): E1284–E1291.

Alkahtani

(2014) Comparing fat oxidation in an exercise test with moderate-intensity interval training. Journal of Sports Science and Medicine 13: 51–58.

Banks

(2001) Enhanced leptin transport across the blood-brain barrier by α1 adrenergic agents. Brain Research 899(1–2): 209–217.

Banks

Farrell

(2003) Impaired transport of leptin across the blood-brain barrier in obesity is acquired and reversible. American Journal of Physiology Endocrinology and Metabolism 285(1): E10–15.

Beachen

Muldoon

Matthews

, et al. (2002) Effects of hemoconcentration and sympathetic activation on serum lipid responses to brief mental stress. Psychosomatic Medicine 64(4): 587–594.

Bellisle

Dalix

(2001) Cognitive restraint can be offset by destruction, leading to increased meal intake in women. American Journal of Clinical Nutrition 74(2): 197–200.

Borg

(1982) Psychophysical bases of perceived exertion. Medicine and Science in Sports and Exercise 14: 377–381.

Brennan

Feltrin

Nair

, et al. (2009) Effects of the phases of the menstrual cycle on gastric emptying, glycemia, plasma GLP-1 and insulin, and energy intake in healthy lean women. American Journal of Physiology Gastrointestinal and Liver Physiology 297(3): G602–G610.

Centers for Disease Control (CDC) (2014) National Health and Nutrition Examination Survey (NHANES): Anthropometry Procedures Manual. CreateSpace Indepedent Publishing Platform.

10.

Chu

Stampfer

Spiegelman

, et al. (2001) Dietary and lifestyle factors in relation to plasma leptin concentrations among normal weight and overweight men. International Journal of Obesity and Related Metabolic Disorders 25(1): 106–114.

11.

Considine

Sinha

Heiman

, et al. (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. The New England Journal of Medicine 334(5): 292–295.

12.

Couillard

Mauriege

Prud’homme

, et al. (2002) Plasma leptin response to an epinephrine infusion in lean and obese women. Obesity Research 10(01): 6–13.

13.

Deighton

Stensel

(2014) Creating an acute energy deficit without stimulating compensatory increases in appetite: Is there an optimal exercise protocol? Proceedings of the Nutrition Society 73(2): 352–358.

14.

Dorling

Broom

Burns

, et al. (2018) Acute and chronic effects of exercise on appetite, energy intake, and appetite-related hormones: The modulating effect of adiposity, sex, and habitual physical activity. Nutrients 10(9):1140.

15.

Douglas

King

McFarlane

, et al. (2015) Appetite, appetite hormone and energy intake responses to two consecutive days of aerobic exercise in healthy young men. Appetite 92: 57–65.

16.

Farooqi

O'Rahilly

(2009) Leptin: a pivotal regulator of human energy homeostasis. American Journal of Clinical Nutrition 89(3): 980S–984S.

17.

Fonseca

(2010) Effects of β-blockers on glucose and lipid metabolism. Current Medical Research and Opinion 26(3): 615–629.

18.

Forster

Macdonald

(1999) The assay of the catecholamine content of small volumes of human plasma. Biomedical Chromatography 13(3): 209–215.

19.

Gustafson

Farrell

Kalkhoff

(1990) Impaired plasma catecholamine response to submaximal treadmill exercise in obese women. Metabolism 39(4): 410–417.

20.

Hartling

Svendsen

Trap-Jensen

(1980) Haemodynamic and metabolic effects of combined adrenergic alpha- and beta-receptor blockade with labetalol in the exercising human forearm. European Journal of Clinical Investigation 10: 431–435.

21.

Heden

Liu

Park

, et al. (2013) Acute aerobic exercise differentially alters acylated ghrelin and perceived fullness in normal-weight and obese individuals. Journal of Applied Physiology 115(5): 680–687.

22.

Holland

Welch

Unwin

, et al. (1993) McCance and Widdowson’s The Composition of Foods. Fifth Edition. The Royal Society of Chemistry & Ministry of Agriculture, Fisheries and Food, Cambridge, Goodfellow & Egan Phototypesetting Ltd.

23.

Horner

Byrne

King

(2014) Reproducibility of subjective appetite ratings and ad libitum test meal energy intake in overweight and obese males. Appetite 81: 116–122.

24.

Keller

Steensberg

, et al. (2005) Leptin gene expression and systemic levels in healthy men: Effect of exercise, carbohydrate, interleukin-6, and epinephrine. Journal of Applied Physiology 98(5): 1805–1812.

25.

King

Garnham

Jackson

, et al. (2015) Appetite-regulatory hormone responses on the day following a prolonged bout of moderate-intensity exercise. Physiology and Behaviour 15: 23–31.

26.

Krawczewski Carhuatanta

Demuro

Tschöp

, et al. (2011) Voluntary exercise improves high-fat diet-induced leptin resistance independent of adiposity. Endocrinology 152(7): 2655–2664.

27.

Ladage

Schwinger

RHG

Brixius

(2013) Cardio-selective beta-blocker: Pharmacological evidence and their influence on exercise capacity. Cardiovascular Therapeutics 31(2): 76–83.

28.

Lara

Taylor

Macdonald

(2010) Is ad libitum energy intake in overweight subjects reproducible in laboratory studies using the preload paradigm? European Journal of Clinical Nutrition 64(9): 1028–1031.

29.

Lean

Finer

(2006) ABC of obesity. Management: Part II-drugs. British Medical Journal 14: 794–797.

30.

Lean

Han

Deurenberg

(1996) Predicting body composition by densitometry from simple anthropometric measurements. American Journal of Clinical Nutrition 63(1): 4–14.

31.

Lean

Malkova

(2016) Altered gut and adipose tissue hormones in overweight and obese individuals: Cause or consequence? International Journal of Obesity 40(4): 622–632.

32.

Lean

MEJ

(2001) How does sibutramine work? International Journal of Obesity and Related Metabolic Disorders 25: S8–11.

33.

MacCarthy

Bloomfield

(1983) Labetalol: A review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy 3(4): 193–219.

34.

Martins

Kulseng

Rehfeld

, et al. (2013) Effect of chronic exercise on appetite control in overweight and obese individuals. Medicine and Science in Sports and Exercise 45(5): 805–812.

35.

Martins

Morgan

Truby

(2008) A review of the effects of exercise on appetite regulation: An obesity perspective. International Journal of Obesity 32(9): 1337–1347.

36.

Maughan

(1982) A simple, rapid method for determination of glucose, lactate, pyruvate, alanine, 3-hydroxybutyrate and acetoacetate in a single 2 µl blood sample. Clinica Chemica Acta 122(2): 231–240.

37.

McLoughlin

Popham

Linton

, et al. (1992) Use of arterialized venous blood sampling during incremental exercise tests. Journal of Applied Physiology 73(3): 937–940.

38.

Morris

Rui

(2009) Recent advances in understanding leptin signaling and leptin resistance. American Journal of Physiology Endocrinology and Metabolism 297(6): E1247–59.

39.

Fleming

Robinson

, et al. (2014) Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 384(9945): 766–781.

40.

Ravussin

Schutz

Acheson

, et al. (1985) Short-term, mixed-diet overfeeding in man: No evidence of “luxuskonsumption”. American Journal of Physiology 249: E470–477.

41.

Ricci

Fried

(1999) Isoproterenol decreases leptin expression in adipose tissue of obese humans. Obesity Research 7(3): 233–240.

42.

Ropelle

Flores

Cintra

, et al. (2010) IL-6 and IL-10 anti-inflammatory activity links exercise to hypothalamic insulin and leptin sensitivity through IKKbeta and ER stress inhibition. PLOS Biology 8(8): e1000465.

43.

Salvadori

Fanari

Giacomotti

, et al. (2003) Kinetics of catecholamines and potassium, and heart rate during exercise testing in obese subjects. Heart rate regulation in obese during exercise. European Journal of Nutrition 42(4): 181–187.

44.

Schubert

Desbrow

Sabapathy

, et al. (2013) Acute exercise and subsequent energy intake. A meta-analysis. Appetite 63: 92–104.

45.

Schulz

Altman

Moher

(2010) CONSORT. Statement: Updated guidelines for reporting parallel group randomized trials. BMC Medicine 8(18): 1–9.

46.

Scriba

Aprath-Husmann

Blum

, et al. (2000) Catecholamines suppress leptin release from in vitro differentiated subcutaneous human adipocytes in primary culture via beta1- and beta2-adrenergic receptors. European Journal of Endocrinology 143(3): 439–445.

47.

Shook

Hand

Drenowatz

, et al. (2015) Low levels of physical activity are associated with dysregulation of energy intake and fat mass gain over 1 year. American Journal of Clinical Nutrition 102(6): 1332–1338.

48.

Stubbs

Hughes

Johnstone

, et al. (2000) The use of visual analogue scales to assess motivation to eat in human subjects: A review of their reliability and validity with an evaluation of new hand-held computerized systems for temporal tracking of appetite ratings. British Journal of Nutrition 84(4): 405–415.

49.

Tham

McKaigue

Guy

, et al. (1993) The dose dependency of the alpha-adrenoceptor antagonist and beta-adrenoceptor partial agonist activity of dilevalol and labetalol in man. British Journal of Clinical Pharmacology 36(3): 251–256.

50.

Tiryaki-Sonmez

Ozen

Bugdayci

, et al. (2013) Effect of exercise on appetite-regulating hormones in overweight women. Biology of Sport 30(2): 75–80.

51.

Tsofliou

Pitsiladis

Malkova

, et al. (2003) Moderate physical activity permits acute coupling between serum leptin and appetite-satiety measures in obese women. International Journal of Obesity and Related Metabolic Disorders 27(11): 1332–1339.

52.

Walsh

Adams

Sinclair

, et al. (1998) Influences on adrenaline-induced thermogenesis in obese women and relationship to cardiovascular responses. Clinical Science 94(2): 121–127.

53.

Webber

Taylor

Greathead

, et al. (1994) A comparison of the thermogenic, metabolic and haemodynamic responses to infused adrenaline in lean and obese subjects. International Journal of Obesity and Related Metabolic Disorders 18(11): 17–24.

54.

Wellman

(2000) Norepinephrine and the control of food intake. Nutrition 16: 837–842.

55.

Wellman

Davies

Morien

, et al. (1993) Modulation of feeding by hypothalamic paraventricular nucleus alpha 1- and alpha 2-adrenergic receptors. Life Sciences 53(9): 669–679.

56.

Westerterp

(2010) Physical activity, food intake, and body weight regulation: insights from doubly labeled water studies. Nutrition Reviews 68(3): 148–154.

57.

Zaccaria

Ermolao

Brugin

, et al. (2013) Plasma leptin and energy expenditure during prolonged, moderate intensity, treadmill exercise. Journal of Endocrinological Investigation 36(6): 396–401.

58.

Zouhal

Lemoine-Morel

Mathieu

, et al. (2013) Catecholamines and obesity: Effects of exercise and training. Sports Medicine 43(7): 591–600.

59.

Zouhal

Sellami

Saeidi

, et al. (2019) Effect of physical exercise and training on gastrointestinal hormones in populations with different weight statuses. Nutrition Reviews 77(7): 455–477.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.09 MB